NEW YORK (GenomeWeb News) – The stock of Quest Diagnostics this week was downgraded by Zacks Equity Research to Underperform. In a statement, the investment research and information firm noted a drop in Quest's revenues and earnings-per-share for continuing operations in the fourth quarter, as well as a "disappointing outlook" for the first quarter of 2013.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.